Orion PharmaDHA:ORIONPHARM -1.05%69 EBIT per Share is BDT-0.61 as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 69/100 and a GF Value™ of BDT20.28 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 337 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 94.66% on this metric.
Orion Pharma's EBIT per Share for the
three
months ended in Mar. 2026 was BDT-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-0.61.
During the past 12 months, the average EBIT per Share Growth Rate of Orion Pharma was -121.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -53.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -38.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -19.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Orion Pharma's EBIT per Share or its related term are showing as below:
DHA:ORIONPHARM'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -53.9 Med: -13.6 Max: 2.6
Current: -53.9
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Orion Pharma was 2.60% per year. The lowest was -53.90% per year. And the median was -13.60% per year.
DHA:ORIONPHARM's 3-Year EBIT Growth Rate is ranked worse than 94.66% of 337
companies
in the Utilities - Independent Power Producers industry
Industry Median: -0.6
vs DHA:ORIONPHARM: -53.90
Orion Pharma's EBIT for the
three
months ended in Mar. 2026 was BDT-2 Mil.
Orion Pharma (DHA:ORIONPHARM) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Orion Pharma EBIT per Share Related Terms
Orion Pharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for Orion Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-0.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a EBIT per Share of BDT-0.61 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Orion Pharma and its competitors. According to the industry distribution chart, Orion Pharma ranks #319 out of 337 companies in the Utilities - Independent Power Producers industry, placing it in the top 94.7%.
Is Orion Pharma's EBIT per Share too high?
Orion Pharma's current EBIT per Share is BDT-0.61. Based on the distribution chart, Orion Pharma ranks #319 out of 337 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's EBIT per Share compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #319 out of 337 companies for EBIT per Share. This places Orion Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for an Utilities - Independent Power Producers company?
A good EBIT per Share depends on the Utilities - Independent Power Producers industry context. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Orion Pharma and its competitors. Orion Pharma's current EBIT per Share is BDT-0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.28, compared to a current price of BDT28.30 — trading 39.5% above its estimated fair value. The current EBIT per Share is BDT-0.61. Orion Pharma's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current EBIT per Share is BDT-0.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.30 is trading 39.5% above its estimated GF Value™ of BDT20.28.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
EBIT per Share: BDT-0.61
GF Value™: BDT20.28 vs. price of BDT28.30 (39.5% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
69GF Score
Get the complete analysis for DHA:ORIONPHARM
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
